FDA clears Foundayo pill
The FDA approved Eli Lilly’s new oral GLP-1 weight-loss drug, Foundayo (orforglipron), which shifts competition in obesity treatment toward pills instead of injections — that matters because pills change access and convenience for people trying to lose weight. (managedhealthcareexecutive.com). The approval was announced on April 9 and sets up a direct rivalry with other oral GLP-1s already entering the market, changing how patients and clinicians choose therapy. (managedhealthcareexecutive.com)
Weight-loss drugs started as weekly shots. Now the fight is moving to the medicine cabinet: the Food and Drug Administration approved Eli Lilly’s once-daily pill Foundayo, the brand name for orforglipron, for adults with obesity or adults who are overweight with at least one weight-related condition. (fda.gov) These drugs copy a gut signal called glucagon-like peptide-1, which is the hormone your body releases after you eat. That signal tells the brain you have had enough and slows how fast food leaves the stomach, which is why people often feel less hungry on these medicines. (nejm.org) The first big obesity winners in this class were injections because the active ingredient was a fragile peptide, which is a protein-like molecule that is hard to get through the stomach intact. Orforglipron is a small molecule instead, so it can be made as a tablet rather than wrapped in a shot pen. (nejm.org) That chemistry changes the daily routine. Lilly says Foundayo is the only approved weight-loss pill in this class that can be taken any time of day without food or water restrictions, which removes the empty-stomach timing rules that have complicated other oral glucagon-like peptide-1 products. (prnewswire.com) The approval also landed unusually fast. The Food and Drug Administration said it cleared Foundayo 50 days after filing and 294 days before the January 20, 2027 target date, making it the first new molecular entity approved under the agency’s National Priority Voucher pilot program and the fastest approval of a new molecular entity since 2002. (fda.gov) The weight-loss numbers that got it there were solid, not magical. In a 72-week phase 3 trial published in The New England Journal of Medicine, average body-weight change was minus 7.5% with 6 milligrams, minus 8.4% with 12 milligrams, and minus 11.2% with 36 milligrams, versus minus 2.1% with placebo. (nejm.org) Lilly framed the same result in pounds: adults on the highest dose lost an average of 27 pounds in the ATTAIN-1 trial. The company also said Foundayo will be offered through LillyDirect with free home delivery, starting at $25 a month for some commercially insured patients and $149 for self-pay patients. (prnewswire.com) The tradeoff looks familiar because the side effects look like the rest of the class. In the phase 3 trial, treatment stopped because of adverse events in 5.3% to 10.3% of patients on orforglipron versus 2.7% on placebo, and the most common problems were stomach-related effects that were mostly mild to moderate. (nejm.org) This is also not a one-company market anymore. Novo Nordisk already has Food and Drug Administration approval for Wegovy tablets, and the current label shows both Wegovy injection and Wegovy tablets as approved forms of semaglutide for chronic weight management. (accessdata.fda.gov) So the next competition is less about proving that glucagon-like peptide-1 drugs work and more about which format fits real life. A weekly injection, a pill with timing rules, and now a pill without food or water restrictions give doctors and patients three different ways to chase the same biology. (prnewswire.com)
